Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AMRN | US
0.00
0.30%
Healthcare
Biotechnology
30/06/2024
04/10/2024
0.61
0.60
0.62
0.57
Amarin Corporation plc a pharmaceutical company engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States European countries Canada Lebanon and the United Arab Emirates. It offers VASCEPA a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co. Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin Ireland.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
44.2%1 month
33.5%3 months
58.1%6 months
71.1%-
500.00
0.45
0.01
0.01
-5.80
0.08
-1.74
-23.79M
249.09M
249.09M
-
-0.78
-94.20
-15.80
-5.98
22.38
4.49
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.09
Range1M
0.09
Range3M
0.25
Rel. volume
1.99
Price X volume
842.61K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.63 | 269.88M | 0.87% | n/a | 1.55% |
Genfit SA | GNFT | Biotechnology | 5.3861 | 268.80M | 4.67% | 13.90 | 104.08% |
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Nanobiotix S.A | NBTX | Biotechnology | 5.19 | 246.03M | 0.00% | n/a | -2742.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.80 | 0.76 | Cheaper |
Ent. to Revenue | 0.08 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.45 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 58.07 | 74.67 | Lower Risk |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 249.09M | 3.73B | Emerging |